Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study

L. Khoja, E. G. Atenafu, S. Suciu, S. Leyvraz, T. Sato, E. Marshall, U. Keilholz, L. Zimmer, S. P. Patel, S. Piperno-Neumann, J. Piulats, T. T. Kivela, C. Pfoehler, S. Bhatia, P. Huppert, L. B. J. Van Iersel, I. J. M. De Vries, N. Penel, T. Vogl, T. ChengG. Fiorentini, F. Mouriaux, A. Tarhini, P. M. Patel, R. Carvajal, A. M. Joshua*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1370-1380
Number of pages11
JournalAnnals of Oncology
Volume30
Issue number8
DOIs
Publication statusPublished - Aug 2019

Keywords

  • meta-analysis
  • uveal melanoma
  • trial design
  • survival benchmarks
  • STAGE-IV MELANOMA
  • PHASE-II TRIAL
  • GEMCITABINE PLUS TREOSULFAN
  • LIVER METASTASES
  • CHEMOEMBOLIZATION TACE
  • CHOROIDAL MELANOMA
  • 1ST-LINE TREATMENT
  • INTRAARTERIAL
  • TEMOZOLOMIDE
  • COMBINATION

Cite this

Khoja, L., Atenafu, E. G., Suciu, S., Leyvraz, S., Sato, T., Marshall, E., Keilholz, U., Zimmer, L., Patel, S. P., Piperno-Neumann, S., Piulats, J., Kivela, T. T., Pfoehler, C., Bhatia, S., Huppert, P., Van Iersel, L. B. J., De Vries, I. J. M., Penel, N., Vogl, T., ... Joshua, A. M. (2019). Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Annals of Oncology, 30(8), 1370-1380. https://doi.org/10.1093/annonc/mdz176